Janus Kinase-2 Mutation Associated Portal Vein Thrombosis Complicating Liver Cirrhosis and Hepatocellular Carcinoma

• DOI: 10.31557/apjcp.2021.22.1.267
• Publication Date: 2021-01-28T16:56:41Z
• Authors: Hatem Rabie; Warda Othman; Dalia M Elsabaawy; Eman Elshemy; Neamat Abdelmageed; Fatma Khalaf; Hanan Bedair
• Keywords: Portal vein thrombosis

Background: Portal vein thrombosis (PVT) might be a catastrophic event complicating liver cirrhosis and hepatocellular carcinoma (HCC). Aim: role of JAK2 RS V617F mutation as risk factor for PVT development in HCC. Methods: A case control study conducted on 100 patients (76 HCC 24 cirrhosis) additionally, healthy individuals used group. was diagnosed incidentally by Doppler ultrasound during routine follow-up screening. Prothrombin G20210A mutation, MTHFR Factor V Leiden (VFL), antithrombin III (ATIII), protein C, S, antiphospholipid antibodies, along with real-time polymerase chain reaction all were analyzed. Results: Patients significantly older (p <0.001), thrombocytopenic high alkaline phosphatase <0.001). found 28/100 (28%) idiopathic carcinoma. Cases positive rs accompanied S deficiency (P 0.03), LA absence 0.06), frequency ascites 0.03). While, the heterozygous (p0.001), ATIII 0.02), VFL 0.01) more frequent negative mutation. The comparison between demographic data thrombophilic parameters cases revealed that no significant differences recorded except male gender, Diabetes Mellitus, splenomegaly increased among <0.05). Conclusions: must considered any without identified factors, potential considerations evolving myeloproliferative disorders. New diagnostic therapeutic implications are still awaited.